VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials

Carolyn Williamson, Lyle Curry, Nonhlanhla N. Mkhize, Elena Giorgi, Craig A. Magaret, Bronwen E. Lambson, Sinethemba Bhebhe, Haajira Kaldine, Thandeka Moyo-Gwete, Morgane Rolland, Raabya Rossenkhan, Nina Marie G. Garcia, Chivonne Moodley, Anna Yssel, Yunda Huang, Alaine A. Marsden, Daniel B. Reeves, Bryan T. Mayer, Roger E. Bumgarner, Nicolas Beaume, Dylan H. Westfall, Michal Juraska, Allan C. DeCamp, Hugh Murrell, Hongjun Bai, Wenjie Deng, Alec Pankow, Tanmoy Bhattacharya, Talita York, Nonkululeko Ndabambi, Lennie Chen, Hong Zhao, Asanda Gwashu-Nyangiri, Ruwayhida Thebus, Paula Marantz Cohen, Ben Murrell, Shelly Karuna, John Hural, Nyaradzo Mgodi, Srilatha Edupuganti, Lynn Morris, David C. Montefiori, M. Juliana McElrath, Myron S. Cohen, Lawrence Corey, Paul T. Edlefsen, Peter B. Gilbert, Penny L. Moore, James I. MullinsbioRxiv 2025 · DOI

TL;DR

This study reveals that the broadly neutralizing antibody VRC01, used in HIV prevention trials, can select for rare escape mutations in the virus shortly after infection. These mutations can reduce the effectiveness of VRC01 and related antibodies, highlighting the need for next-generation antibodies with broader coverage and higher potency for durable HIV prevention.

What Problem Does This Paper Address?

Broadly neutralizing antibodies (bnAbs) are a promising strategy for preventing HIV infection. However, a major challenge is the virus's ability to evolve and develop resistance to these antibodies. The Antibody Mediated Prevention (AMP) trials investigated the efficacy of VRC01, a bnAb targeting the CD4 binding site (CD4bs) of the HIV envelope protein, in preventing HIV acquisition. While VRC01 was effective against sensitive HIV strains, its impact on viral evolution after infection, particularly the emergence of resistance, was not fully understood. This paper addresses the critical question of whether VRC01, when administered prophylactically, can drive the selection of de novo (newly arising) escape mutations in individuals who become infected, and if so, how these mutations affect susceptibility to other CD4bs bnAbs.

Methods

The researchers analyzed over 12,000 HIV env gene sequences from 47 participants in the AMP trials. They employed deep sequencing to identify viral variants. To pinpoint escape mutations, they compared sequences from VRC01-treated participants to those from placebo recipients. They also used neutralization assays with pseudoviruses (viruses engineered to display specific HIV envelope proteins) to assess the impact of identified mutations on VRC01 sensitivity and the sensitivity to other CD4bs bnAbs. Structural modeling was used to visualize the location of these mutations within the VRC01 epitope.

Datasets

The study utilized HIV env gene sequences from participants in the Antibody Mediated Prevention (AMP) trials (HVTN 703/HPTN 081 and HVTN 704/HPTN 085). They also used a global database of HIV-1 sequences (from Los Alamos HIV sequence database) to assess the frequency of identified escape mutations in circulating viruses.

Key Insights and Ideas

  • VRC01 isn't a perfect shield: While VRC01 is effective, it's not impenetrable. The study shows it can actively select for viral escape mutations shortly after infection.
  • Escape mutations are rare but potent: The identified escape mutations are uncommon in the general HIV population, suggesting they might impose a fitness cost on the virus. However, even at low frequencies, they can significantly reduce VRC01's effectiveness.
  • Cross-resistance is a concern: Mutations conferring resistance to VRC01 can also reduce sensitivity to other CD4bs bnAbs, complicating treatment and prevention strategies that rely on this class of antibodies.
  • Potency matters: More potent bnAbs, like N6 and 1-18, showed greater resilience to these VRC01-selected escape mutations, highlighting the importance of antibody potency in overcoming viral evolution.
  • Timing is crucial: The emergence of escape mutations was observed in individuals diagnosed with HIV relatively soon after their last VRC01 infusion, suggesting that maintaining sufficient antibody levels is key.

Key Results

  • VRC01-mediated de novo escape mutations were identified in 8 out of 26 VRC01-treated participants, but in none of the 21 placebo participants.
  • These escape mutations were found at very low frequencies (<1%) in global HIV sequences.
  • The escape mutations were primarily located in the Loop-D and β23/V5 regions of the HIV Env protein.
  • These mutations conferred cross-resistance to several CD4bs bnAbs, but more potent bnAbs like N6 and 1-18 largely retained their activity.
  • In some cases, double mutations were observed to confer even greater cross-resistance than single mutations.

Limitations and Future Work

  • Transient pressure: The authors note that VRC01 pressure is transient, which might limit the opportunity for compensatory mutations to arise and fully restore viral fitness.
  • Incomplete neutralization: The study raises concerns about whether resistant variants will persist and potentially undermine future antibody-based interventions, especially if they can be transmitted.
  • Distal sites and multiple lineages: The study did not assess escape mutations at distal sites outside the VRC01 epitope, nor did it investigate multiple lineage infections where recombination could facilitate escape.
  • Future directions: The findings underscore the need for next-generation bnAbs with improved breadth and potency to enhance the durability and efficacy of antibody-based HIV prevention. Future work should focus on understanding the long-term impact of these escape mutations on viral fitness and transmission, and on developing combination antibody strategies that target multiple epitopes to overcome resistance.

Summary updated

Abstract

Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bNAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post-acquisition is not fully understood. Here we analyzed >12,000 HIV env sequences from 47 participants from the AMP trials, identifying VRC01-mediated <i>de novo</i> escape mutations in 8 of 26 VRC01-treated participants but none in 21 placebo participants. These mutations were found at very low frequency (<1%) in global viruses. Escape mutations, primarily located in the Loop-D and β23/V5 regions of Env, conferred cross-resistance to several CD4bs bnAbs, while more potent CD4bs bnAbs like N6 and 1-18 largely retained their activity. Our findings demonstrate that prophylactic VRC01 can select for viral escape after infection, underscoring the need for next-generation bnAbs with improved breadth and potency to enhance durability and efficacy of antibody-based HIV prevention.
BibTeX
@misc{williamson2025vrc,
  author = {Carolyn Williamson and Lyle Curry and Nonhlanhla N. Mkhize and Elena Giorgi and Craig A. Magaret and Bronwen E. Lambson and Sinethemba Bhebhe and Haajira Kaldine and Thandeka Moyo-Gwete and Morgane Rolland and Raabya Rossenkhan and Nina Marie G. Garcia and Chivonne Moodley and Anna Yssel and Yunda Huang and Alaine A. Marsden and Daniel B. Reeves and Bryan T. Mayer and Roger E. Bumgarner and Nicolas Beaume and Dylan H. Westfall and Michal Juraska and Allan C. DeCamp and Hugh Murrell and Hongjun Bai and Wenjie Deng and Alec Pankow and Tanmoy Bhattacharya and Talita York and Nonkululeko Ndabambi and Lennie Chen and Hong Zhao and Asanda Gwashu-Nyangiri and Ruwayhida Thebus and Paula Marantz Cohen and Ben Murrell and Shelly Karuna and John Hural and Nyaradzo Mgodi and Srilatha Edupuganti and Lynn Morris and David C. Montefiori and M. Juliana McElrath and Myron S. Cohen and Lawrence Corey and Paul T. Edlefsen and Peter B. Gilbert and Penny L. Moore and James I. Mullins},
  title = {{VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials}},
  year = {2025},
  doi = {10.1101/2025.10.29.685411},
  howpublished = {bioRxiv},
}

Loading related content...

Figure